The adverse effect of metabolic syndrome on left ventricular global strains and myocardial energetic efficiency in non-ischemic dilated cardiomyopathy patients: a cardiac magnetic resonance study
Authors' conclusion
The presence of MetS worsens LV function, remodeling, and myocardial energetic efficiency in patients with NIDCM, as evidenced by declines in LV strain, global function parameters, and indexed myocardial energetic efficiency. These findings suggest that addressing metabolic abnormalities may be crucial for improving LV function and outcomes for patients with NIDCM.
Study context
- Population
- Non-ischemic dilated cardiomyopathy patients who underwent cardiovascular magnetic resonance (CMR) examination
- Participants
- 557 participants
- Exposure
- Non-ischemic dilated cardiomyopathy (NIDCM) with metabolic syndrome (MetS) vs without MetS
- NIDCM(MetS+)n = 179
- NIDCM(MetS-)n = 378reference
- Outcome
- Indexed myocardial energetic efficiency (MEEI)
Methodological detailscardiac magnetic resonance
- Cardiac magnetic resonance
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Left ventricular (LV) function and remodeling
- MetS: significantly lower LVSVI, LVEF and LVGFI, higher LVMI and LVRI (all p < 0.05)
- No significant differences in LVEDVI and LVESVI (both p > 0.05)
LV strain
- MetS+: worse global peak strain and peak diastolic strain rate in all three directions, decreased radial and longitudinal peak systolic strain rate (PSSR) (all p < 0.05)
- Circumferential PSSR did not differ significantly (p > 0.05)
Multivariable linear regression: MetS as independent determinant
- LV global longitudinal peak strain (GLPS) β, p < 0.001
- 0.211
- LVRI β, p = 0.003
- 0.147
- Myocardial energetic efficiency (MEEI) β, p < 0.001
- - 0.160
Original publication
The adverse effect of metabolic syndrome on left ventricular global strains and myocardial energetic efficiency in non-ischemic dilated cardiomyopathy patients: a cardiac magnetic resonance study. Cardiovasc Diabetol. Published 20 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →